Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C29726
Created by
admin on Wed Apr 02 01:55:31 GMT 2025 , Edited by admin on Wed Apr 02 01:55:31 GMT 2025
|
||
|
FDA ORPHAN DRUG |
47190
Created by
admin on Wed Apr 02 01:55:31 GMT 2025 , Edited by admin on Wed Apr 02 01:55:31 GMT 2025
|
||
|
EU-Orphan Drug |
EU/3/00/003
Created by
admin on Wed Apr 02 01:55:31 GMT 2025 , Edited by admin on Wed Apr 02 01:55:31 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
REPLAGAL (AUTHORIZED: FABRY DISEASE)
Created by
admin on Wed Apr 02 01:55:31 GMT 2025 , Edited by admin on Wed Apr 02 01:55:31 GMT 2025
|
||
|
WHO-ATC |
A16AB03
Created by
admin on Wed Apr 02 01:55:31 GMT 2025 , Edited by admin on Wed Apr 02 01:55:31 GMT 2025
|
||
|
WHO-VATC |
QA16AB03
Created by
admin on Wed Apr 02 01:55:31 GMT 2025 , Edited by admin on Wed Apr 02 01:55:31 GMT 2025
|
||
|
FDA ORPHAN DRUG |
601617
Created by
admin on Wed Apr 02 01:55:31 GMT 2025 , Edited by admin on Wed Apr 02 01:55:31 GMT 2025
|
||
|
FDA ORPHAN DRUG |
58691
Created by
admin on Wed Apr 02 01:55:31 GMT 2025 , Edited by admin on Wed Apr 02 01:55:31 GMT 2025
|
||
|
FDA ORPHAN DRUG |
112998
Created by
admin on Wed Apr 02 01:55:31 GMT 2025 , Edited by admin on Wed Apr 02 01:55:31 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
2HLC17MX9G
Created by
admin on Wed Apr 02 01:55:31 GMT 2025 , Edited by admin on Wed Apr 02 01:55:31 GMT 2025
|
PRIMARY | |||
|
Agalsidase Alfa
Created by
admin on Wed Apr 02 01:55:31 GMT 2025 , Edited by admin on Wed Apr 02 01:55:31 GMT 2025
|
PRIMARY | |||
|
m5636
Created by
admin on Wed Apr 02 01:55:31 GMT 2025 , Edited by admin on Wed Apr 02 01:55:31 GMT 2025
|
PRIMARY | Merck Index | ||
|
LL-03
Created by
admin on Wed Apr 02 01:55:31 GMT 2025 , Edited by admin on Wed Apr 02 01:55:31 GMT 2025
|
PRIMARY | |||
|
104138-64-9
Created by
admin on Wed Apr 02 01:55:31 GMT 2025 , Edited by admin on Wed Apr 02 01:55:31 GMT 2025
|
GENERIC (FAMILY) | |||
|
259351
Created by
admin on Wed Apr 02 01:55:31 GMT 2025 , Edited by admin on Wed Apr 02 01:55:31 GMT 2025
|
PRIMARY | |||
|
C74209
Created by
admin on Wed Apr 02 01:55:31 GMT 2025 , Edited by admin on Wed Apr 02 01:55:31 GMT 2025
|
PRIMARY | |||
|
CHEMBL2108214
Created by
admin on Wed Apr 02 01:55:31 GMT 2025 , Edited by admin on Wed Apr 02 01:55:31 GMT 2025
|
PRIMARY | |||
|
9025-35-8
Created by
admin on Wed Apr 02 01:55:31 GMT 2025 , Edited by admin on Wed Apr 02 01:55:31 GMT 2025
|
ALTERNATIVE | |||
|
5021
Created by
admin on Wed Apr 02 01:55:31 GMT 2025 , Edited by admin on Wed Apr 02 01:55:31 GMT 2025
|
PRIMARY | |||
|
100000092056
Created by
admin on Wed Apr 02 01:55:31 GMT 2025 , Edited by admin on Wed Apr 02 01:55:31 GMT 2025
|
PRIMARY | |||
|
8048
Created by
admin on Wed Apr 02 01:55:31 GMT 2025 , Edited by admin on Wed Apr 02 01:55:31 GMT 2025
|
PRIMARY | |||
|
C416903
Created by
admin on Wed Apr 02 01:55:31 GMT 2025 , Edited by admin on Wed Apr 02 01:55:31 GMT 2025
|
PRIMARY | |||
|
232-792-0
Created by
admin on Wed Apr 02 01:55:31 GMT 2025 , Edited by admin on Wed Apr 02 01:55:31 GMT 2025
|
PRIMARY | |||
|
SUB12456MIG
Created by
admin on Wed Apr 02 01:55:31 GMT 2025 , Edited by admin on Wed Apr 02 01:55:31 GMT 2025
|
PRIMARY |
ACTIVE MOIETY